Markers of exacerbation severity in chronic obstructive pulmonary disease

[1]  K. Kubo,et al.  Airway inflammation during stable and acutely exacerbated chronic obstructive pulmonary disease , 2005, European Respiratory Journal.

[2]  John R Hurst,et al.  Exacerbations and time spent outdoors in chronic obstructive pulmonary disease. , 2005, American journal of respiratory and critical care medicine.

[3]  M. R. Rutten-van Mölken,et al.  Resource use and risk factors in high-cost exacerbations of COPD. , 2004, Respiratory medicine.

[4]  W. MacNee,et al.  Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper , 2004, European Respiratory Journal.

[5]  R. Pauwels,et al.  COPD exacerbations: the importance of a standard definition. , 2004, Respiratory medicine.

[6]  Joan B Soriano,et al.  The proportional Venn diagram of obstructive lung disease: two approximations from the United States and the United Kingdom. , 2003, Chest.

[7]  E. Wouters,et al.  Bacterial infections in patients requiring admission for an acute exacerbation of COPD; a 1-year prospective study. , 2003, Respiratory medicine.

[8]  I. Stiell,et al.  Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. , 2003, The New England journal of medicine.

[9]  J. Wedzicha,et al.  COPD exacerbations: definitions and classifications , 2003, European Respiratory Journal.

[10]  T. Seemungal,et al.  Viral infections in obstructive airway diseases , 2003, Current opinion in pulmonary medicine.

[11]  J. Ayres,et al.  Cost-effectiveness of fluticasone propionate in the treatment of chronic obstructive pulmonary disease: a double-blind randomized, placebo-controlled trial. , 2003, Respiratory medicine.

[12]  R. Pauwels,et al.  Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial , 2003, The Lancet.

[13]  P. Jones,et al.  Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations , 2003, European Respiratory Journal.

[14]  T. Seemungal,et al.  Chlamydia pneumoniae and COPD exacerbation , 2002, Thorax.

[15]  T. Seemungal,et al.  Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease , 2002, Thorax.

[16]  N. Pride,et al.  Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice , 2002, European Respiratory Journal.

[17]  P. Coyle,et al.  Exacerbations of chronic obstructive pulmonary disease , 2002, Thorax.

[18]  T. Seemungal,et al.  Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations , 2002, Thorax.

[19]  N. Anthonisen.  Bacteria and exacerbations of chronic obstructive pulmonary disease. , 2002, The New England journal of medicine.

[20]  J. Wedzicha.  Exacerbations Etiology and Pathophysiologic Mechanisms , 2002, Chest.

[21]  Joan B Soriano,et al.  Chronic obstructive pulmonary disease in the United Kingdom: trends in mortality, morbidity, and smoking , 2002, Current opinion in pulmonary medicine.

[22]  E Monsó,et al.  Risk factors for hospitalization for a chronic obstructive pulmonary disease exacerbation. EFRAM study. , 2001, American journal of respiratory and critical care medicine.

[23]  L. Fabbri,et al.  Exacerbations of Bronchitis: bronchial eosinophilia and gene expression for interleukin-4, interleukin-5, and eosinophil chemoattractants. , 2001, American journal of respiratory and critical care medicine.

[24]  A. Agustí,et al.  Supported discharge shortens hospital stay in patients hospitalized because of an exacerbation of COPD. , 2001, The European respiratory journal.

[25]  D. Mccrory,et al.  Management of Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Summary and Appraisal of Published Evidence , 2001, Annals of Internal Medicine.

[26]  P. Barnes,et al.  Chronic obstructive pulmonary disease. , 2000, The New England journal of medicine.

[27]  N. MacIntyre,et al.  Management of acute exacerbations of chronic obstructive pulmonary disease. , 2000, Evidence report/technology assessment.

[28]  N. Pride,et al.  Recent trends in physician diagnosed COPD in women and men in the UK , 2000, Thorax.

[29]  T. Seemungal,et al.  Acute Exacerbations of Chronic Obstructive Pulmonary Disease Are Accompanied by Elevations of Plasma Fibrinogen and Serum IL-6 Levels , 2000, Thrombosis and Haemostasis.

[30]  R. Rodríguez-Roisín,et al.  Toward a consensus definition for COPD exacerbations. , 2000, Chest.

[31]  T. Seemungal,et al.  Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. , 2000, American journal of respiratory and critical care medicine.

[32]  T. Seemungal,et al.  Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations , 2000, Thorax.

[33]  T. Seemungal,et al.  Effect of temperature on lung function and symptoms in chronic obstructive pulmonary disease. , 1999, The European respiratory journal.

[34]  R J Cook,et al.  Two-state mixed renewal processes for chronic disease. , 1999, Statistics in medicine.

[35]  T. Seemungal,et al.  Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. , 1998, American journal of respiratory and critical care medicine.

[36]  J. Govan,et al.  Value of C-reactive protein measurements in exacerbations of chronic obstructive pulmonary disease. , 1998, Respiratory medicine.

[37]  F. Forastiere,et al.  Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. , 1997, The European respiratory journal.

[38]  J. Barberà,et al.  Mechanisms of worsening gas exchange during acute exacerbations of chronic obstructive pulmonary disease. , 1997, The European respiratory journal.

[39]  L Goldman,et al.  Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments) , 1996, American journal of respiratory and critical care medicine.

[40]  L. Fabbri,et al.  Airway eosinophilia and expression of interleukin‐5 protein in asthma and in exacerbations of chronic bronchitis , 1996, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[41]  W. Knaus,et al.  Hospital and 1-Year Survival of Patients Admitted to Intensive Care Units With Acute Exacerbation of Chronic Obstructive Pulmonary Disease , 1995 .

[42]  L. Fabbri,et al.  Airway eosinophilia in chronic bronchitis during exacerbations. , 1994, American journal of respiratory and critical care medicine.

[43]  A. Connors,et al.  Relationship between arterial blood gases and spirometry in acute exacerbations of chronic obstructive pulmonary disease. , 1989, Annals of emergency medicine.

[44]  W. Gibbons,et al.  Determinants of weaning and survival among patients with COPD who require mechanical ventilation for acute respiratory failure. , 1989, Chest.

[45]  N. Anthonisen,et al.  Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. , 1987, Annals of internal medicine.

[46]  D. Flenley,et al.  RESPIRATORY FAILURE REVISITED: ACUTE EXACERBATIONS OF CHRONIC BRONCHITIS BETWEEN 1961-68 AND 1970-76 , 1980, The Lancet.

[47]  I. Munro.  AN UNSTEADY BALANCE BETWEEN PRIVATE AND PUBLIC Historical Foundations and Economic Realities in Australia , 1976, The Lancet.

[48]  B. Burrows,et al.  Treatment of acute respiratory acidosis in chronic obstructive lung disease. , 1971, JAMA.

[49]  Pieter Zanen,et al.  Markers of inflammation and oxidative stress in exacerbated chronic obstructive pulmonary disease patients. , 2005, Respiratory medicine.

[50]  D. Hunninghake.  Cardiovascular disease in chronic obstructive pulmonary disease. , 2005, Proceedings of the American Thoracic Society.

[51]  Jan B Oostenbrink,et al.  Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[52]  Neil B. Pride,et al.  Validation of general practitioner-diagnosed COPD in the UK General Practice Research Database , 2004, European Journal of Epidemiology.

[53]  N. Pride,et al.  Inhaled Corticosteroids With/Without Long-Acting β-Agonists Reduce the Risk of Rehospitalization and Death in COPD Patients , 2003, American journal of respiratory medicine : drugs, devices, and other interventions.

[54]  Jack L. Vevea,et al.  Fixed- and random-effects models in meta-analysis. , 1998 .

[55]  R. Cook,et al.  Modeling Two-state Disease Processes with Random Effects , 1997, Lifetime data analysis.

[56]  R. Rodríguez-Roisín.  Pulmonary gas exchange in acute respiratory failure. , 1994, European journal of anaesthesiology.

[57]  F. Portier,et al.  Determinants of immediate survival among chronic respiratory insufficiency patients admitted to an intensive care unit for acute respiratory failure. A prospective multicenter study. The French Task Group for Acute Respiratory Failure in Chronic Respiratory insufficiency. , 1992, Chest.